Clinical trial · Observational
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma
An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient as per routine clinical practice of the Investigator (maximum of 52 weeks, until disease progression /unacceptable toxicity or withdrawal of consent) and/or based on the local label.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Safety: Incidence of adverse events
- timeFrame
- approximately 4 years
Secondary outcomes (3)
- measure
- Progression-free survival: time from first drug administration to documented disease progression or death of any cause
- timeFrame
- approximately 4 years
- measure
- Overall response rate: complete response or partial response according to RECIST criteria
- timeFrame
- approximately 4 years
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Advanced and/or metastatic renal cell carcinoma * Receiving first-line treatment with Avastin and interferon alpha-2a according to standard of care and current local label * At least one measurable and non-measurable lesion according to RECIST criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate bone marrow, renal and liver function Exclusion Criteria: * Contraindications to Avastin and/or interferon alpha-2a as per local label
References
Publications (0)
Data not yet available